Transdermal Delivery of Glimepiride: A Novel Approach Using Nanomicelle-Embedded Microneedles
Pharmaceutics · 26.07.2023 · 15 (8) · 2019
DOI: 10.3390/pharmaceutics15082019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 26.07.2023. Verfasst von Sadia Pervez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Peshawar, Peshawar 25000, Pakistan. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fawaz Alasmari, Deputyship for Research and Innovation, “Ministry of Education” in Saudi Arabia.
Abstract (Originalsprache)
Glimepiride (GM) is a hydrophobic drug that dissolves slowly and yields inconsistent clinical responses after oral administration. Transdermal drug delivery (TDD) is an appropriate alternative to oral administration. Microneedles (MNs) offer a promising delivery system that penetrates the skin, while polymeric micelles can enhance the solubility; hence, the combination of both results in high drug bioavailability. This study aims to improve glimepiride’s solubility, dissolution rate, and bioavailability by incorporating nanomicelles into MNs for TDD. The nanomicelles formulated with 10% Soluplus® (SP) and 40% GM had a mean particle size of 82.6 ± 0.54, PDI of 0.1 ± 0.01, −16.2 ± 0.18 zeta potential, and achieved a 250-fold increase in solubility. The fabricated pyramid shaped GM-dissolving MNs were thermally stable and had no formulation incompatibility, as confirmed by thermal and FTIR analysis. The in vitro dissolution profile revealed that the GM release from nanomicelles and nanomicelle-loaded DMN was concentration-independent following non-Fickian transport mechanism. Improved pharmacokinetic parameters were obtained with dose of 240 µg as compared to 1 mg of GM oral tablet, in healthy human volunteers. The observed Cmax, Tmax and MRT were 1.56 μg/mL ± 0.06, 4 h, and 40.04 h ± 3.37, respectively. The safety profile assessment indicated that microneedles are safe with no adverse effects on skin or health. This study provides an alternative delivery system for the administration of glimepiride, resulting in improved bioavailability, enhanced patient compliance, and reduced dosing frequency.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, University of Peshawar, Peshawar 25000, Pakistan.
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
- Department of Pharmacy, Qurtaba University of Science and Information Technology, Peshawar 25000, Pakistan.
ORCID-Profile: Fazli Nasir, Fawaz Alasmari, Arbab Tahir
Förderung
- Fawaz Alasmari
- Deputyship for Research and Innovation, “Ministry of Education” in Saudi Arabia
Zitieren
APA
Pervez, S., Nasir, F., Hidayatullah, T., Khattak, M. A., Alasmari, F., Zainab, S. R., Gohar, S., Tahir, A., & Maryam, G. E. (2023). Transdermal Delivery of Glimepiride: A Novel Approach Using Nanomicelle-Embedded Microneedles. Pharmaceutics, 15(8), 2019. https://doi.org/10.3390/pharmaceutics15082019
Vancouver
Pervez S, Nasir F, Hidayatullah T, Khattak MA, Alasmari F, Zainab SR, et al. Transdermal Delivery of Glimepiride: A Novel Approach Using Nanomicelle-Embedded Microneedles. Pharmaceutics. 2023;15(8):2019. doi:10.3390/pharmaceutics15082019
BibTeX
@article{Pervez2023,
author = {Pervez, Sadia and Nasir, Fazli and Hidayatullah, Talaya and Khattak, Muzna Ali and Alasmari, Fawaz and Zainab, Syeda Rabqa and Gohar, Shazma and Tahir, Arbab and Maryam, Gul E},
title = {Transdermal Delivery of Glimepiride: A Novel Approach Using Nanomicelle-Embedded Microneedles},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {8},
pages = {2019},
doi = {10.3390/pharmaceutics15082019}
}
EUVIMED